Phase IIb, randomised, placebo-controlled study of SGLT2 inhibitor empagliflozin in T2D

March 01, 2013

E Ferrannin et al. Diabetes, Obesity and Metabolism. Doi: 10.1111/dom.12081

This trial recruited 408 patients and evaluated the efficacy, safety, tolerability and pharmacokinetics of empagliflozin in patients with type 2 diabetes.

It found that in patients with type 2 diabetes empagliflozin resulted in dose-dependent, clinically meaningful reductions in HbA1c and fasting plasma glucose, and reductions in body weight compared with placebo.

Article information
Topic:
News
Author:
Source:
Diabetes, Obesity and Metabolism
Added:
Mar 01, 2013
Free HCP newsletter
Join the newsletter
Free weekly news
Latest diabetes healthcare news direct to your inbox.
Email:
Profession:
NHS employee:
Latest forum posts
The latest forum threads from the Ask a Question forum.
Healthcare Search